He previously served as a?Tenured Professor of Biochemistry and Molecular Biology?at the?Indiana University School of Medicine, where he also directed the?Protein Center. He was a?Co-Principal Investigator?for the?Clinical Proteomic Technologies for Cancer Initiative?at the?National Cancer Institute (NCI). Additionally, he has served as a?review expert?for grant applications funded by the?National Institutes of Health (NIH)?and the?U.S. Department of Defense. In 2004, he was awarded the?Young Investigator Award?by the?Human Proteome Organization (HUPO). He has published nearly?100 high-impact research papers, which have been cited over?7,400 times, with an?H-Index of 46. He also serves as a?peer reviewer?for more than ten high-impact scientific journals.
His primary research areas include: Mechanisms of DNA repair in mammalian systems, Mechanisms of cancer chemotherapy resistance and the development of sensitizing agents, Exploration of drug targets for prostate cancer, Etiology of Parkinson’s disease and the application of clinical biomarkers.
Team members/Experts/ Consultants
Dr Xin Liu, Associate Professor
Dr Xin Liu received her bachelor degree in Bioinformatics from Tongji University. She received her PhD degree in bioinformatics and drug design from National University of Singapore. Her research centers around systems biology and computer aided drug design. She has published 10 peer-reviewed papers in such top journals in the field of medicinal chemistry as Current Medicinal Chemistry, PNAS and Nucleic Acids Research. Her primary research areas include: Systems analysis of cross-talks between pathways facilitating (Enabling drug target identification and advancing system-level understanding of diseases),Development of machine learning based QASR method(for high throughput screening of novel drug hits), Biomarker discovery(by high throughput –omics data mining by incorporating consensus scoring of multiple random sampling and multistep evaluation of gene-ranking consistency for maximally avoiding erroneous elimination of predictor genes).
Dr Ken Cheng, Associate Professor
She has broad experience in mass spectrometry and NMR-based comprehensive metabolomics and lipidomics studies. She?specializes in multi-omics data (particularly metabolomics, proteomics, and gut microbiome) and multidimensional data integration methods. Her expertise includes exploring novel biomarkers, developing diagnostic and predictive models, and investigating the regulatory mechanisms of bioactive compounds in metabolic diseases.
Dr Mingming Xu, Associate ProfessorReceived his PhD degree from Griffith University, Australia. Before joining Xi’an Jiaotong-Liverpool University, he did postdoctoral research at Soochow University for over two years. His previous researches include development of fluorescent probes for the diagnosis of Alzheimer’s disease, mass spectrometry-based discovery of small molecule inhibitors against alpha-synuclein aggregation, and discovery of biomarkers for Parkinson’s disease and pancreatic cancer via glycoproteomics. Dr. Xu’s current research primarily focuses on Drug discovery and mechanistic studies for common neurodegenerative diseases, Identification of exosomal biomarkers from biofluids for common cancers, Mass spectrometry-based biomarker discovery.
Ying Chen, Director of the Central Laboratory
Graduated with a bachelor’s degree from Shandong University and a master’s degree from Soochow University. She conducted research on the functional identification of novel genes involved in the transformation of neural stem cells into glioma. After completing graduate studies, joined Xi’an Jiaotong-Liverpool University.? She primarily engaged in proteomic analysis of tumor cells. She has broad extensive experience in the development of bioanalytical methods for both large and small molecule drugs using mass spectrometry.
Changping Dai, technician
Graduated from Soochow University. After graduation, he worked for Hengrui Pharmaceutical Co., Ltd., mainly in quality control. Able to evaluate drug metabolism by using LC-MS/MS to perform pharmacokinetic studies and detect real-time changes in plasma concentration. At the same time, he worked for a year in the compatibility study of plastic materials for drug production and contact surfaces.
Yang He,technician
Graduated from Jilin University in 2020 with a Master’s degree, specializing in pharmacokinetics and metabolomics of traditional Chinese medicine, and published 4 SCI papers as the first author. After graduation, joined the Analytical Department of WuXi Biologics in Suzhou, responsible for the development of analytical methods for various drugs (small molecules, polymers, and oligonucleotides). In 2023, joined Xi’an Jiao tong-Liverpool University, primarily engaged in the development of quantitative methods and detection research for various substances, with extensive experience in mass spectrometry research.
Yue Wang, technician
In 2022, she obtained a master’s degree from Jiangsu University. During her studies, she was mainly engaged in biosensors and their applications in pollutant analysis. Currently working at the Center for Pharmaceutical Analysis of Xi’an Jiaotong-Liverpool University, she is mainly engaged in molecular interaction research and is responsible for the application of biacore analysis technology.
Ling Sun, technician
with a bachelor’s degree and a master’s degree in biochemistry from Nanjing University of Technology, engaged in quality research of chemical raw materials, familiar with drug development processes and quality control standards for one and a half years in a drug R&D company. And has more than 6 years of relevant work experience in GLP laboratory, primarily responsible for the management of samples and reagents. Involved in drug metabolism studies and skilled in using mass spectrometry methods for the analysis of biological samples.。
Director of the unit
Professor Mu Wang, Director of the Center
He previously served as a?Tenured Professor of Biochemistry and Molecular Biology?at the?Indiana University School of Medicine, where he also directed the?Protein Center. He was a?Co-Principal Investigator?for the?Clinical Proteomic Technologies for Cancer Initiative?at the?National Cancer Institute (NCI). Additionally, he has served as a?review expert?for grant applications funded by the?National Institutes of Health (NIH)?and the?U.S. Department of Defense. In 2004, he was awarded the?Young Investigator Award?by the?Human Proteome Organization (HUPO). He has published nearly?100 high-impact research papers, which have been cited over?7,400 times, with an?H-Index of 46. He also serves as a?peer reviewer?for more than ten high-impact scientific journals.
His primary research areas include: Mechanisms of DNA repair in mammalian systems, Mechanisms of cancer chemotherapy resistance and the development of sensitizing agents, Exploration of drug targets for prostate cancer, Etiology of Parkinson’s disease and the application of clinical biomarkers.
Team members/Experts/ Consultants
Dr Xin Liu, Associate Professor
Dr Xin Liu received her bachelor degree in Bioinformatics from Tongji University. She received her PhD degree in bioinformatics and drug design from National University of Singapore. Her research centers around systems biology and computer aided drug design. She has published 10 peer-reviewed papers in such top journals in the field of medicinal chemistry as Current Medicinal Chemistry, PNAS and Nucleic Acids Research. Her primary research areas include: Systems analysis of cross-talks between pathways facilitating (Enabling drug target identification and advancing system-level understanding of diseases),Development of machine learning based QASR method(for high throughput screening of novel drug hits), Biomarker discovery(by high throughput –omics data mining by incorporating consensus scoring of multiple random sampling and multistep evaluation of gene-ranking consistency for maximally avoiding erroneous elimination of predictor genes).
Dr Ken Cheng, Associate Professor
She has broad experience in mass spectrometry and NMR-based comprehensive metabolomics and lipidomics studies. She?specializes in multi-omics data (particularly metabolomics, proteomics, and gut microbiome) and multidimensional data integration methods. Her expertise includes exploring novel biomarkers, developing diagnostic and predictive models, and investigating the regulatory mechanisms of bioactive compounds in metabolic diseases.
Dr Mingming Xu, Associate ProfessorReceived his PhD degree from Griffith University, Australia. Before joining Xi’an Jiaotong-Liverpool University, he did postdoctoral research at Soochow University for over two years. His previous researches include development of fluorescent probes for the diagnosis of Alzheimer’s disease, mass spectrometry-based discovery of small molecule inhibitors against alpha-synuclein aggregation, and discovery of biomarkers for Parkinson’s disease and pancreatic cancer via glycoproteomics. Dr. Xu’s current research primarily focuses on Drug discovery and mechanistic studies for common neurodegenerative diseases, Identification of exosomal biomarkers from biofluids for common cancers, Mass spectrometry-based biomarker discovery.
Ying Chen, Director of the Central Laboratory
Graduated with a bachelor’s degree from Shandong University and a master’s degree from Soochow University. She conducted research on the functional identification of novel genes involved in the transformation of neural stem cells into glioma. After completing graduate studies, joined Xi’an Jiaotong-Liverpool University.? She primarily engaged in proteomic analysis of tumor cells. She has broad extensive experience in the development of bioanalytical methods for both large and small molecule drugs using mass spectrometry.
Changping Dai, technician
Graduated from Soochow University. After graduation, he worked for Hengrui Pharmaceutical Co., Ltd., mainly in quality control. Able to evaluate drug metabolism by using LC-MS/MS to perform pharmacokinetic studies and detect real-time changes in plasma concentration. At the same time, he worked for a year in the compatibility study of plastic materials for drug production and contact surfaces.
Yang He,technician
Graduated from Jilin University in 2020 with a Master’s degree, specializing in pharmacokinetics and metabolomics of traditional Chinese medicine, and published 4 SCI papers as the first author. After graduation, joined the Analytical Department of WuXi Biologics in Suzhou, responsible for the development of analytical methods for various drugs (small molecules, polymers, and oligonucleotides). In 2023, joined Xi’an Jiao tong-Liverpool University, primarily engaged in the development of quantitative methods and detection research for various substances, with extensive experience in mass spectrometry research.
Yue Wang, technician
In 2022, she obtained a master’s degree from Jiangsu University. During her studies, she was mainly engaged in biosensors and their applications in pollutant analysis. Currently working at the Center for Pharmaceutical Analysis of Xi’an Jiaotong-Liverpool University, she is mainly engaged in molecular interaction research and is responsible for the application of biacore analysis technology.
Ling Sun, technician
with a bachelor’s degree and a master’s degree in biochemistry from Nanjing University of Technology, engaged in quality research of chemical raw materials, familiar with drug development processes and quality control standards for one and a half years in a drug R&D company. And has more than 6 years of relevant work experience in GLP laboratory, primarily responsible for the management of samples and reagents. Involved in drug metabolism studies and skilled in using mass spectrometry methods for the analysis of biological samples.。